Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AI-061 in Advanced Solid Tumors
NCT05858736Phase 1Completed
- Sponsor
- OncoC4
- Start
- Jul 2023
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of AI-061 in solid tumor (3 arms), sponsored by OncoC4. Primary endpoints: Dose Limiting Toxicity at 21 days, Maximum Toxicity Dose at 21 days and 2 more. Started Jul 2023; status: completed.
02
Drugs
AI-061
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05858736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05858736.